{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:15:37Z","timestamp":1792091737781,"version":"4.4.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T00:00:00Z","timestamp":1742601600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008457","name":"University of Virginia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008457","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.cllc.2025.03.006","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T21:16:35Z","timestamp":1743196595000},"page":"347-353.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Real-World Outcomes of Tarlatamab in Small Cell Lung Cancer, Including Patients With Untreated Brain Metastases"],"prefix":"10.1016","volume":"26","author":[{"given":"Fabian J.","family":"Bolte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean C.","family":"Dougherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail O.","family":"Danos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alia C.","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaroslav","family":"Shvorak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Statler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan D.","family":"Gentzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5812-8857","authenticated-orcid":false,"given":"Richard D.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.cllc.2025.03.006_bib0002","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","article-title":"Small-cell lung cancer","volume":"7","author":"Rudin","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"11","key":"10.1016\/j.cllc.2025.03.006_bib0003","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/j.ebiom.2015.09.031","article-title":"Associated links among smoking, chronic obstructive pulmonary disease, and small cell Lung Cancer: a pooled analysis in the International Lung Cancer Consortium","volume":"2","author":"Huang","year":"2015","journal-title":"EBioMedicine"},{"issue":"9494","key":"10.1016\/j.cllc.2025.03.006_bib0004","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0140-6736(05)67569-1","article-title":"Small-cell lung cancer","volume":"366","author":"Jackman","year":"2005","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.cllc.2025.03.006_bib0005","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/cncr.20043","article-title":"Neurologic disorders in 432 consecutive patients with small cell lung carcinoma","volume":"100","author":"Seute","year":"2004","journal-title":"Cancer"},{"issue":"23","key":"10.1016\/j.cllc.2025.03.006_bib0006","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"issue":"10212","key":"10.1016\/j.cllc.2025.03.006_bib0007","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.cllc.2025.03.006_bib0008","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1470-2045(20)30068-1","article-title":"Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial","volume":"21","author":"Trigo","year":"2020","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.cllc.2025.03.006_bib0009","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1200\/JCO.1999.17.2.658","article-title":"Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer","volume":"17","author":"von Pawel","year":"1999","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.cllc.2025.03.006_bib0010","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/bjc.1998.54","article-title":"A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer","volume":"77","author":"Smit","year":"1998","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.cllc.2025.03.006_bib0011","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1158\/1078-0432.CCR-11-2059","article-title":"Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker","volume":"18","author":"Pietanza","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"16","key":"10.1016\/j.cllc.2025.03.006_bib0012","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1200\/JCO.22.02823","article-title":"Tarlatamab, a first-in-class DLL3-targeted bispecific T-cell engager, in recurrent small-cell lung cancer: an open-label, phase I study","volume":"41","author":"Paz-Ares","year":"2023","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.cllc.2025.03.006_bib0013","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","article-title":"Tarlatamab for patients with previously treated small-cell lung cancer","volume":"389","author":"Ahn","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.cllc.2025.03.006_bib0014","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.cllc.2025.03.006_bib0015","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.cllc.2025.03.006_bib0016","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s13311-016-0507-6","article-title":"Modified criteria for radiographic response assessment in glioblastoma clinical trials","volume":"14","author":"Ellingson","year":"2017","journal-title":"Neurotherapeutics"},{"issue":"12","key":"10.1016\/j.cllc.2025.03.006_bib0017","article-title":"First report of response to Tarlatamab in a patient with DLL3-positive pulmonary carcinoid: case report","volume":"5","author":"Cooper","year":"2024","journal-title":"JTO Clin Res Rep"},{"issue":"29","key":"10.1016\/j.cllc.2025.03.006_bib0018","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1200\/JCO.24.00553","article-title":"Sustained clinical benefit and intracranial activity of Tarlatamab in previously treated small cell lung cancer: deLLphi-300 trial update","volume":"42","author":"Dowlati","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152573042500052X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152573042500052X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T07:29:02Z","timestamp":1777793342000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152573042500052X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S152573042500052X"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2025.03.006","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Outcomes of Tarlatamab in Small Cell Lung Cancer, Including Patients With Untreated Brain Metastases","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2025.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}